{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:52:21Z","timestamp":1781877141799,"version":"3.54.5"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T00:00:00Z","timestamp":1781827200000},"content-version":"vor","delay-in-days":50,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"by Shanghai Committee of Science and Technology","award":["25ZR1402331"],"award-info":[{"award-number":["25ZR1402331"]}]},{"name":"by Shanghai Committee of Science and Technology","award":["25ZR1402331"],"award-info":[{"award-number":["25ZR1402331"]}]},{"name":"by Shanghai Committee of Science and Technology","award":["25ZR1402331"],"award-info":[{"award-number":["25ZR1402331"]}]},{"name":"by Shanghai Committee of Science and Technology","award":["25ZR1402331"],"award-info":[{"award-number":["25ZR1402331"]}]},{"name":"by Shanghai Committee of Science and Technology","award":["25ZR1402331"],"award-info":[{"award-number":["25ZR1402331"]}]},{"name":"by Shanghai Committee of Science and Technology","award":["25ZR1402331"],"award-info":[{"award-number":["25ZR1402331"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"DOI":"10.1186\/s12872-026-05892-9","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T01:15:18Z","timestamp":1777511718000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal remodeling of atherosclerotic lipoprotein profiles and inflammatory markers after percutaneous coronary intervention: a real-world longitudinal study"],"prefix":"10.1186","volume":"26","author":[{"given":"An","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyang","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghua","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"7855","key":"5892_CR1","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/s41586-021-03392-8","volume":"592","author":"P Libby","year":"2021","unstructured":"Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524\u201333.","journal-title":"Nature"},{"issue":"32","key":"5892_CR2","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"BA Ference","year":"2017","unstructured":"Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459\u201372.","journal-title":"Eur Heart J"},{"issue":"23","key":"5892_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1016\/j.jacc.2009.09.009","volume":"54","author":"P Libby","year":"2009","unstructured":"Libby P, Ridker PM, Hansson GK. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129\u201338.","journal-title":"J Am Coll Cardiol"},{"key":"5892_CR4","doi-asserted-by":"publisher","first-page":"4904217","DOI":"10.1155\/2020\/4904217","volume":"2020","author":"H Wang","year":"2020","unstructured":"Wang H, Liu Z, Shao J, Lin L, Jiang M, Wang L, et al. Immune and Inflammation in Acute Coronary Syndrome: Molecular Mechanisms and Therapeutic Implications. J Immunol Res. 2020;2020:4904217.","journal-title":"J Immunol Res"},{"issue":"38","key":"5892_CR5","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023;44(38):3720\u2013826.","journal-title":"Eur Heart J"},{"issue":"1","key":"5892_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388.","journal-title":"Eur Heart J"},{"issue":"1","key":"5892_CR7","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","volume":"118","author":"PM Ridker","year":"2016","unstructured":"Ridker PM. From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection. Circ Res. 2016;118(1):145\u201356.","journal-title":"Circ Res"},{"issue":"12","key":"5892_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med. 2017;377(12):1119\u201331.","journal-title":"N Engl J Med"},{"issue":"8","key":"5892_CR9","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.jacasi.2024.05.004","volume":"4","author":"M Yu","year":"2024","unstructured":"Yu M, Yuan YF, Yang F, Xu JH, Liu ML, Nie SF, et al. Residual Inflammatory Risk in Outcomes of Chinese Patients After Percutaneous Coronary Intervention. JACC Asia. 2024;4(8):636\u20138.","journal-title":"JACC Asia"},{"issue":"2","key":"5892_CR10","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1046\/j.1365-2796.2003.01276.x","volume":"255","author":"G Walldius","year":"2004","unstructured":"Walldius G, Jungner I. Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J Intern Med. 2004;255(2):188\u2013205.","journal-title":"J Intern Med"},{"issue":"23","key":"5892_CR11","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","volume":"31","author":"BG Nordestgaard","year":"2010","unstructured":"Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31(23):2844\u201353.","journal-title":"Eur Heart J"},{"issue":"39","key":"5892_CR12","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","volume":"43","author":"F Kronenberg","year":"2022","unstructured":"Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, et al. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J. 2022;43(39):3925\u201346.","journal-title":"Eur Heart J"},{"issue":"11","key":"5892_CR13","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.5551\/jat.60152","volume":"28","author":"T Sekimoto","year":"2021","unstructured":"Sekimoto T, Koba S, Mori H, Sakai R, Arai T, Yokota Y, et al. Small Dense Low-Density Lipoprotein Cholesterol: A Residual Risk for Rapid Progression of Non-Culprit Coronary Lesion in Patients with Acute Coronary Syndrome. J Atheroscler Thromb. 2021;28(11):1161\u201374.","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"5892_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12872-021-01979-7","volume":"21","author":"J Zhang","year":"2021","unstructured":"Zhang J, He L. Relationship between small dense low density lipoprotein and cardiovascular events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. 2021;21(1):169.","journal-title":"BMC Cardiovasc Disord"},{"issue":"7","key":"5892_CR15","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1093\/clinchem\/hvae061","volume":"70","author":"S Koba","year":"2024","unstructured":"Koba S, Satoh N, Ito Y, Yokota Y, Tsunoda F, Sakai K, et al. Impact of Direct Measurement of Small Dense Low-Density Lipoprotein Cholesterol for Long-Term Secondary Prevention in Patients with Stable Coronary Artery Disease. Clin Chem. 2024;70(7):957\u201366.","journal-title":"Clin Chem"},{"issue":"26","key":"5892_CR16","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"381","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019;381(26):2497\u2013505.","journal-title":"N Engl J Med"},{"issue":"19","key":"5892_CR17","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, Eikelboom JW, Schut A, Opstal TSJ, et al. Colchicine in Patients with Chronic Coronary Disease. N Engl J Med. 2020;383(19):1838\u201347.","journal-title":"N Engl J Med"},{"issue":"12","key":"5892_CR18","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.jacc.2020.07.033","volume":"76","author":"M Sud","year":"2020","unstructured":"Sud M, Han L, Koh M, Abdel-Qadir H, Austin PC, Farkouh ME, et al. Low-Density Lipoprotein Cholesterol and Adverse Cardiovascular Events After Percutaneous Coronary Intervention. J Am Coll Cardiol. 2020;76(12):1440\u201350.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"5892_CR19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/a-2009-5077","volume":"148","author":"PE St\u00fcrzebecher","year":"2023","unstructured":"St\u00fcrzebecher PE, T\u00fcnnemann-Tarr A, Tuppatsch K, Laufs U. [Treatment and LDL cholesterol adjustment in patients with high and very high cardiovascular risk in Germany compared with Europe - data from the SANTORINI registry]. Dtsch Med Wochenschr. 2023;148(9):55\u201364.","journal-title":"Dtsch Med Wochenschr"},{"key":"5892_CR20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.atherosclerosis.2017.02.003","volume":"259","author":"Y Li","year":"2017","unstructured":"Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, et al. Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis. 2017;259:75\u201382.","journal-title":"Atherosclerosis"},{"issue":"18","key":"5892_CR21","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"MS Sabatine","year":"2017","unstructured":"Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017;376(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"22","key":"5892_CR22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"GG Schwartz","year":"2018","unstructured":"Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379(22):2097\u2013107.","journal-title":"N Engl J Med"},{"issue":"25","key":"5892_CR23","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"CP Cannon","year":"2015","unstructured":"Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med. 2015;372(25):2387\u201397.","journal-title":"N Engl J Med"},{"issue":"15","key":"5892_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","volume":"350","author":"CP Cannon","year":"2004","unstructured":"Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495\u2013504.","journal-title":"N Engl J Med"},{"issue":"2","key":"5892_CR25","doi-asserted-by":"publisher","first-page":"104409","DOI":"10.1016\/j.numecd.2025.104409","volume":"36","author":"RCM Intravaia","year":"2026","unstructured":"Intravaia RCM, Tognola C, Maloberti A, Brucato F, Campione E, Giannattasio C, et al. The role of inflammation in acute coronary syndrome: A systematic review on biochemical inflammatory assessment and anti-inflammatory therapies. Nutr Metabolism Cardiovasc Dis. 2026;36(2):104409.","journal-title":"Nutr Metabolism Cardiovasc Dis"},{"issue":"21","key":"5892_CR26","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr., Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207.","journal-title":"N Engl J Med"},{"issue":"2","key":"5892_CR27","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nri3793","volume":"15","author":"AR Tall","year":"2015","unstructured":"Tall AR, Yvan-Charvet L. Cholesterol, inflammation and innate immunity. Nat Rev Immunol. 2015;15(2):104\u201316.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5892_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13098-025-01687-8","volume":"17","author":"A Gao","year":"2025","unstructured":"Gao A, Peng B, Gao Y, Yang Z, Li Z, Guo T, et al. Evaluation and comparison of inflammatory and insulin resistance indicators on recurrent cardiovascular events in patients undergoing percutaneous coronary intervention: a single center retrospective observational study. Diabetol Metab Syndr. 2025;17(1):157.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"5892_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12944-025-02537-2","volume":"24","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Li K, Bo X, Zhang Y, Xiao T, Liu H, et al. Effects of residual inflammatory and cholesterol risks on cardiovascular events with evolocumab in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Lipids Health Dis. 2025;24(1):123.","journal-title":"Lipids Health Dis"},{"issue":"12","key":"5892_CR30","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"ML O\u2019Donoghue","year":"2019","unstructured":"O\u2019Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, et al. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation. 2019;139(12):1483\u201392.","journal-title":"Circulation"},{"issue":"22","key":"5892_CR31","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","volume":"316","author":"SJ Nicholls","year":"2016","unstructured":"Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, et al. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. JAMA. 2016;316(22):2373\u201384.","journal-title":"JAMA"},{"issue":"18","key":"5892_CR32","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","volume":"327","author":"L R\u00e4ber","year":"2022","unstructured":"R\u00e4ber L, Ueki Y, Otsuka T, Losdat S, H\u00e4ner JD, Lonborg J, et al. Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. JAMA. 2022;327(18):1771\u201381.","journal-title":"JAMA"},{"issue":"5","key":"5892_CR33","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1161\/01.ATV.15.5.551","volume":"15","author":"KJ Williams","year":"1995","unstructured":"Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15(5):551\u201361.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7293","key":"5892_CR34","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","volume":"464","author":"P Duewell","year":"2010","unstructured":"Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature. 2010;464(7293):1357\u201361.","journal-title":"Nature"},{"issue":"9","key":"5892_CR35","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/nm.3258","volume":"19","author":"CS Robbins","year":"2013","unstructured":"Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, et al. Local proliferation dominates lesional macrophage accumulation in atherosclerosis. Nat Med. 2013;19(9):1166\u201372.","journal-title":"Nat Med"},{"issue":"10","key":"5892_CR36","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nri3520","volume":"13","author":"KJ Moore","year":"2013","unstructured":"Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol. 2013;13(10):709\u201321.","journal-title":"Nat Rev Immunol"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-026-05892-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-026-05892-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T13:05:10Z","timestamp":1781874310000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12872-026-05892-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5892"],"URL":"https:\/\/doi.org\/10.1186\/s12872-026-05892-9","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research conducted in this study adhered to the principles outlined in the Declaration of Helsinki and was approved by the Ethics Committee of Shanghai Jiao Tong University School of Medicine (Ethical code No. XS8749A45).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"522"}}